tegafur has been researched along with Diarrhea in 81 studies
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this single-arm phase II clinical trial was to evaluate whether the alternate-day administration of S-1 plus irinotecan would reduce the incidence of severe diarrhea in comparison to consecutive-day S-1 administration (standard IRIS regimen) in second-line treatment for patients with metastatic colorectal cancer." | 9.27 | A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study. ( Honda, M; Kim, HM; Kondo, K; Kosugi, C; Matsuda, C; Mishima, H; Oba, K; Sakamoto, J; Takahashi, T; Takemoto, H; Tanaka, C; Tokunaga, Y, 2018) |
| "Gemcitabine (GEM) plus cisplatin (CDDP) chemotherapy has been used worldwide as the standard first-line treatment for advanced biliary tract cancer (BTC)." | 9.24 | A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer. ( Arima, S; Furuse, J; Kasuga, A; Kawai, K; Kitamura, H; Kobayashi, T; Nagashima, F; Naruge, D; Okamoto, T; Okano, N; Shimizu, K; Sugiyama, M; Suzuki, Y; Takasu, A; Toki, M, 2017) |
| "In Japan, a study comparing the effectiveness and safety of irinotecan plus S-1 (IRIS) with those of a combination of 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as second-line treatment in patients with advanced or recurrent colorectal cancer demonstrated that IRIS was non-inferior to FOLFIRI." | 9.16 | Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. ( Fukushima, H; Hatanaka, K; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kudo, M; Meguro, T; Miyagishima, T; Munakata, M; Nakamura, M; Nakatsumi, H; Sakata, Y; Sogabe, S; Tateyama, M; Yuki, S, 2012) |
| "Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was recently approved for the treatment of advanced hepatocellular carcinoma (HCC)." | 9.14 | Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. ( Chen, PJ; Cheng, AL; Ding, YH; Hsu, C; Hsu, CH; Lin, ZZ; Shao, YY; Shen, YC, 2010) |
| "This phase II trial was performed to evaluate the efficacy and tolerability of a new combination of Uracil/Ftorafur (UFT)/leucovorin (LV) and oxaliplatin in patients (pts) with metastatic colorectal cancer (MCRC) who had not received prior chemotherapy for metastatic disease." | 9.12 | 'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'. ( Bennouna, J; Bordenave, S; Cvitkovic, F; Dorval, E; Douillard, JY; Hebbar, M; Jacob, JH; Malek, K; Paillot, B; Perrier, H; Priou, F; Seitz, JF; Tonelli, D, 2006) |
| "A combination of irinotecan with continuous intravenous infusions of 5-fluorouracil (5-FU) and leucovorin (LV) is often used to treat advanced colorectal cancer." | 9.12 | Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. ( Goto, A; Hamaguchi, T; Kato, K; Muro, K; Shimada, Y; Shirao, K; Yamada, Y; Yasui, H, 2006) |
| "A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan." | 9.11 | UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. ( Civitelli, S; Correale, P; De Martino, A; Fiaschi, AI; Francini, G; Giorgi, G; Lorenzi, M; Marsili, S; Marzocca, G; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M; Tani, F; Tanzini, G, 2004) |
| "Low dose oral Folinic acid was used together with uracil with ftorafur (UFT) producing some response with low toxicity in advanced colorectal cancer." | 9.09 | Uracil with ftorafur and low dose oral folinic acid in advanced colorectal cancer. ( Arch-Yaemsuan, P; Boonnuch, W; Chakrapee-Sirisuk, S; Lert-Akayamanee, N; Lohsiriwat, D; Nimmanwudipong, T; Sinlarat, P; Srimuninnimit, V; Vathanophas, V, 2001) |
| "Both the biochemical modulation and the continuous administration of 5-fluorouracil (5-FU) have achieved promising results in patients with gastric carcinoma." | 9.08 | Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group. ( Belón, J; Blanco, E; Espinosa, E; Feliu, J; García-Alfonso, P; García-Girón, C; Garrido, P; Gómez-Navarro, J; González Barón, M; Ordónez, A; Zamora, P, 1996) |
| "A significant response rate with oral tegafur and folinic acid in patients with heavily pretreated breast cancer was found." | 9.08 | Phase II trial of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer. ( Albanell, J; Bellmunt, J; Carulla, J; Gallego, OS; Ribas, A; Solé, LA, 1995) |
| "The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer." | 8.87 | Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011) |
| "Gemcitabine has been standard of care in advanced pancreatic adenocarcinomas (PC) for almost two decades." | 7.88 | S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma. ( Bjerregaard, JK; Ejlsmark, MW; Jensen, HA; Krogh, M; Pfeiffer, P; Schonnemann, KR; Winther, SB, 2018) |
| "The uracil/tegafur (UFT) plus oral Leucovorin (LV) regimen is one of the standard chemotherapy modalities for colorectal cancer, and has been reported to have fewer side effects." | 7.73 | [Efficacy of uracil/tegafur (UFT) plus oral Leucovorin (LV) therapy for colorectal cancer in elderly patients]. ( Hoki, M; Ito, T; Iwamoto, T; Iwase, K; Kanou, T; Mizuno, H; Mizushima, T; Nakamori, Y; Ozawa, H; Souma, Y, 2006) |
| " In a previous study, the authors demonstrated that the combination of uracil and tegafur (UFT) with leucovorin (LV) was active and well tolerated in patients with advanced colorectal carcinoma (ACC)." | 7.69 | Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group. ( Colmenarejo, A; de Castro, J; de la Gándara, I; Espinosa, E; Espinosa, J; Feliu, J; Fernández, Y; García Girón, C; González Barón, M; Jalón, JI, 1997) |
| "A comparative study was performed to evaluate the efficacy and safety of 5'-DFUR and tegafur in recurrent breast cancer." | 7.67 | [A comparative study of 5'-DFUR and tegafur in recurrent breast cancer]. ( Abe, O; Ogawa, N; Taguchi, T; Terasawa, T; Tominaga, T; Yoshida, Y, 1985) |
| ") UFT (250 mg/m(2)/day) for 21 days of a 28-day cycle combined with increasing intravenous (i." | 6.70 | Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer. ( Alonso, V; Antón, A; Escudero, P; Herrero, A; Isla, MD; Martinez-Trufero, J; Mayordomo, JI; Sáenz, A; Tres, A; Zorrilla, M, 2001) |
| "The aim of this single-arm phase II clinical trial was to evaluate whether the alternate-day administration of S-1 plus irinotecan would reduce the incidence of severe diarrhea in comparison to consecutive-day S-1 administration (standard IRIS regimen) in second-line treatment for patients with metastatic colorectal cancer." | 5.27 | A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study. ( Honda, M; Kim, HM; Kondo, K; Kosugi, C; Matsuda, C; Mishima, H; Oba, K; Sakamoto, J; Takahashi, T; Takemoto, H; Tanaka, C; Tokunaga, Y, 2018) |
| "Gemcitabine (GEM) plus cisplatin (CDDP) chemotherapy has been used worldwide as the standard first-line treatment for advanced biliary tract cancer (BTC)." | 5.24 | A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer. ( Arima, S; Furuse, J; Kasuga, A; Kawai, K; Kitamura, H; Kobayashi, T; Nagashima, F; Naruge, D; Okamoto, T; Okano, N; Shimizu, K; Sugiyama, M; Suzuki, Y; Takasu, A; Toki, M, 2017) |
| "The incidence of diarrhea during chemotherapy was significantly lower in the S-1 plus lafutidine group than in the group treated with S-1 alone (10% vs." | 5.19 | Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer. ( Hanazaki, K; Kitagawa, H; Kobayashi, M; Maeda, H; Munekage, E; Namikawa, T, 2014) |
| "In Japan, a study comparing the effectiveness and safety of irinotecan plus S-1 (IRIS) with those of a combination of 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as second-line treatment in patients with advanced or recurrent colorectal cancer demonstrated that IRIS was non-inferior to FOLFIRI." | 5.16 | Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. ( Fukushima, H; Hatanaka, K; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kudo, M; Meguro, T; Miyagishima, T; Munakata, M; Nakamura, M; Nakatsumi, H; Sakata, Y; Sogabe, S; Tateyama, M; Yuki, S, 2012) |
| "Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was recently approved for the treatment of advanced hepatocellular carcinoma (HCC)." | 5.14 | Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. ( Chen, PJ; Cheng, AL; Ding, YH; Hsu, C; Hsu, CH; Lin, ZZ; Shao, YY; Shen, YC, 2010) |
| "A combination of irinotecan with continuous intravenous infusions of 5-fluorouracil (5-FU) and leucovorin (LV) is often used to treat advanced colorectal cancer." | 5.12 | Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. ( Goto, A; Hamaguchi, T; Kato, K; Muro, K; Shimada, Y; Shirao, K; Yamada, Y; Yasui, H, 2006) |
| "Tegafur is an oral fluorouracil prodrug used in the treatment of colorectal cancer." | 5.12 | A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule. ( Bennouna, J; Cardot, JM; Château, Y; Douillard, JY; Etienne-Grimaldi, MC; François, E; Gamelin, E; Milano, G; Renée, N, 2007) |
| "This phase II trial was performed to evaluate the efficacy and tolerability of a new combination of Uracil/Ftorafur (UFT)/leucovorin (LV) and oxaliplatin in patients (pts) with metastatic colorectal cancer (MCRC) who had not received prior chemotherapy for metastatic disease." | 5.12 | 'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'. ( Bennouna, J; Bordenave, S; Cvitkovic, F; Dorval, E; Douillard, JY; Hebbar, M; Jacob, JH; Malek, K; Paillot, B; Perrier, H; Priou, F; Seitz, JF; Tonelli, D, 2006) |
| "The purpose of this study was to evaluate the efficacy, assessed as response rate, and toxicity of UFT (Tegafur-Uracil) in combination with oxaliplatin as first-line treatment of advanced colorectal cancer (CRC)." | 5.11 | Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer. ( Antón-Aparicio, L; Aparicio, J; Constela, M; Dorta, FJ; Feliu, J; Fonseca, E; García-Girón, C; Gonzalez-Baron, M; Lomas, M; Vicent, JM, 2004) |
| "A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan." | 5.11 | UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. ( Civitelli, S; Correale, P; De Martino, A; Fiaschi, AI; Francini, G; Giorgi, G; Lorenzi, M; Marsili, S; Marzocca, G; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M; Tani, F; Tanzini, G, 2004) |
| "Low dose oral Folinic acid was used together with uracil with ftorafur (UFT) producing some response with low toxicity in advanced colorectal cancer." | 5.09 | Uracil with ftorafur and low dose oral folinic acid in advanced colorectal cancer. ( Arch-Yaemsuan, P; Boonnuch, W; Chakrapee-Sirisuk, S; Lert-Akayamanee, N; Lohsiriwat, D; Nimmanwudipong, T; Sinlarat, P; Srimuninnimit, V; Vathanophas, V, 2001) |
| "A significant response rate with oral tegafur and folinic acid in patients with heavily pretreated breast cancer was found." | 5.08 | Phase II trial of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer. ( Albanell, J; Bellmunt, J; Carulla, J; Gallego, OS; Ribas, A; Solé, LA, 1995) |
| "Both the biochemical modulation and the continuous administration of 5-fluorouracil (5-FU) have achieved promising results in patients with gastric carcinoma." | 5.08 | Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group. ( Belón, J; Blanco, E; Espinosa, E; Feliu, J; García-Alfonso, P; García-Girón, C; Garrido, P; Gómez-Navarro, J; González Barón, M; Ordónez, A; Zamora, P, 1996) |
| "Thirty-nine patients with locally advanced or metastatic gastric carcinoma received oral UFT (tegafur and uracil) plus leucovorin." | 5.08 | A phase II trial. Oral UFT and leucovorin in patients with advanced gastric carcinoma. ( Kim, BS; Kim, JG; Kim, JS; Kim, YH; Park, YT; Shin, SW, 1997) |
| "The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer." | 4.87 | Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011) |
| "Gemcitabine has been standard of care in advanced pancreatic adenocarcinomas (PC) for almost two decades." | 3.88 | S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma. ( Bjerregaard, JK; Ejlsmark, MW; Jensen, HA; Krogh, M; Pfeiffer, P; Schonnemann, KR; Winther, SB, 2018) |
| "The uracil/tegafur (UFT) plus oral Leucovorin (LV) regimen is one of the standard chemotherapy modalities for colorectal cancer, and has been reported to have fewer side effects." | 3.73 | [Efficacy of uracil/tegafur (UFT) plus oral Leucovorin (LV) therapy for colorectal cancer in elderly patients]. ( Hoki, M; Ito, T; Iwamoto, T; Iwase, K; Kanou, T; Mizuno, H; Mizushima, T; Nakamori, Y; Ozawa, H; Souma, Y, 2006) |
| "Concomitant treatment with 5-fluorouracil (5-FU) and Leucovorin (LV) is positioned as the standard chemotherapy against colorectal cancer." | 3.72 | [Home chemotherapy by concomitant UFT + Leucovorin (po.) in postoperative colorectal cancer patients assessed with Dukes D and curability C colorectal cancer]. ( Anazawa, S; Hirai, K; Kawahara, H; Ogawa, M; Sakuyama, T; Sato, K; Takao, Y; Yamazaki, Y; Yokoyama, M, 2004) |
| " In a previous study, the authors demonstrated that the combination of uracil and tegafur (UFT) with leucovorin (LV) was active and well tolerated in patients with advanced colorectal carcinoma (ACC)." | 3.69 | Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group. ( Colmenarejo, A; de Castro, J; de la Gándara, I; Espinosa, E; Espinosa, J; Feliu, J; Fernández, Y; García Girón, C; González Barón, M; Jalón, JI, 1997) |
| "Twenty-four patients with metastatic breast cancer that had progressed after high-dose chemotherapy with peripheral blood progenitor cell (PBPC) support were given intramuscular methotrexate in combination with oral UFT (tegafur and uracil) and oral leucovorin (the MUL regimen)." | 3.69 | Preliminary results. UFT/methotrexate/leucovorin for breast Ca patients in progression after HDCT/PBPC support. ( Ayala, F; Casado, A; Diaz-Rubio, E; López-Martin, JA; Martin, M; Nieto, Y; Rodriguez-Lescure, A, 1997) |
| "A comparative study was performed to evaluate the efficacy and safety of 5'-DFUR and tegafur in recurrent breast cancer." | 3.67 | [A comparative study of 5'-DFUR and tegafur in recurrent breast cancer]. ( Abe, O; Ogawa, N; Taguchi, T; Terasawa, T; Tominaga, T; Yoshida, Y, 1985) |
| "The incidence of oral mucositis was significantly lower in the treatment group (9." | 2.90 | A prospective pilot study of an elemental nutritional supplement for prevention of oral mucositis during S-1 adjuvant chemotherapy for gastric cancer. ( Kimura, A; Kogure, N; Kuwano, H; Mochiki, E; Ogata, K; Suzuki, M; Toyomasu, Y; Yanai, M; Yanoma, T, 2019) |
| "Unresectable advanced hepatocellular carcinoma is a heterogeneous disease, for which sorafenib is the first targeted agent approved for first-line therapy, and treatment options for patients with sorafenib-refractory advanced hepatocellular carcinoma are limited." | 2.84 | S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial. ( Date, Y; Fang, X; Furuse, J; Hidaka, H; Ikeda, M; Kaneko, S; Kawazoe, S; Kudo, M; Moriguchi, M; Numata, K; Ohkawa, S; Okusaka, T; Sato, Y; Takeuchi, M; Tanaka, H, 2017) |
| "Irinotecan was administered on days 1, 8, 22, and 29." | 2.82 | A multicenter phase I study of preoperative chemoradiotherapy with S-1 and irinotecan for locally advanced lower rectal cancer (SAMRAI-1). ( Baba, H; Hayakawa, K; Hiraoka, M; Ikushima, H; Kamikonya, N; Kato, D; Nemoto-Murofushi, K; Noda, M; Oya, M; Oya, N; Sakai, Y; Sato, T; Shimada, M; Takeuchi, M; Tomita, N; Watanabe, M; Watanabe, T, 2016) |
| "This phase I trial of preoperative S-1 in combination with oxaliplatin and radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis revealed that the recommended dose of oxaliplatin was 60 mg/m(2) weekly." | 2.80 | A phase I trial of preoperative S-1 in combination with oxaliplatin and pelvic radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis. ( Fujita, S; Hamaguchi, T; Ito, Y; Kinugasa, Y; Moriya, Y; Noura, S; Ohue, M; Saito, N; Sakai, D; Shimada, Y, 2015) |
| "Patients with advanced pancreatic cancer who had received no prior chemotherapy were eligible for this study." | 2.79 | A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer. ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Saito, K; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Yamamoto, K; Yamamoto, N, 2014) |
| "To evaluate the efficacy and safety of weekly paclitaxel combined with S-1 or fluorouracil in the first line treatment of advanced gastric carcinoma." | 2.77 | [A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma]. ( Ba, Y; Deng, T; Guo, ZQ; Hu, CH; Huang, DZ; Meng, JC; Wan, HP; Wang, ML; Xiong, JP; Xu, N; Yan, Z; Yao, Y; Yu, Z; Yu, ZH; Zhang, Y; Zheng, RS; Zhuang, ZX, 2012) |
| "54 postoperative colorectal cancer patients received the combination therapy of oxaliplatin and S-1 regimen, repeated every 3 weeks, and evaluate the efficacy after 3 cycles." | 2.76 | [Efficacy and side effects of combination therapy of oxaliplatin and S-1 for colorectal cancer]. ( Jin, ZM; Zhu, QC, 2011) |
| "Diarrhea was the most common type of nonhematologic toxicity: 3 patients had Grade 3 diarrhea." | 2.76 | A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate. ( Hatate, K; Hayakawa, K; Ihara, A; Koizumi, W; Naito, M; Nakamura, T; Okayasu, I; Onosato, W; Ozawa, H; Sato, T; Watanabe, M; Yamashita, K, 2011) |
| "We developed a combination chemotherapy, comprising weekly dosing of iv cisplatin (days 1 and 8) combined with a fixed dose (70 mg/m2/day) of S-1 (days 1-14) for patients with metastatic gastric cancer." | 2.72 | [S-1 combined with weekly dosing of cisplatin for metastatic gastric cancer]. ( Hyodo, I, 2006) |
| ") gemcitabine (GEM) at low dose plus oral chemotherapy with uracil-tegafur (UFT) and cyclophosphamide (CPA) in combination with radiotherapy (RT) against recurrent and advanced pancreatic cancers." | 2.71 | Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer. ( Endo, S; Hashimoto, K; Higami, T; Itakura, M; Koike, M; Maruyama, R; Nio, Y; Tsuji, M; Yamaguchi, K; Yano, S, 2005) |
| ") UFT (250 mg/m(2)/day) for 21 days of a 28-day cycle combined with increasing intravenous (i." | 2.70 | Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer. ( Alonso, V; Antón, A; Escudero, P; Herrero, A; Isla, MD; Martinez-Trufero, J; Mayordomo, JI; Sáenz, A; Tres, A; Zorrilla, M, 2001) |
| " The potential benefit of long bioavailability and oral delivery of UFT compares favorably with continuous infusion regimens without the added morbidity of a catheter and pump." | 2.69 | A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer. ( Bonner, JA; Childs, HA; Newsome, J; Raben, D; Robert, F; Spencer, SA, 2000) |
| "The main toxicity was diarrhea and oral mucositis." | 2.68 | Phase II trial of Oral UFT and leucovorin in advanced gastric carcinoma. ( Cheong, SK; Kim, JS; Kim, YH; Lee, JD; Park, JS; Shin, SW, 1996) |
| "Gastric cancer is the most chemosensitive adenocarcinoma among digestive neoplasms." | 2.68 | The UFT/leucovorin/etoposide regimen for the treatment of advanced gastric cancer. Oncopaz Cooperative Group. ( Belón, J; de Castro, J; Espinosa, E; Feliu, J; García Alfonso, P; García Girón, C; Garrido, P; González Barón, M; Lomas, M; Ordóñez, A; Zamora, P, 1997) |
| " Intolerance to single dosing was clearly demonstrated, and only the split dosing was advanced to 500 mg/m2/day." | 2.68 | Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil. ( Chan, KK; Groshen, S; Jeffers, S; Leichman, CG; Leichman, L; Muggia, FM; Spicer, D; Wu, X, 1996) |
| " After reducing the dosage of S-1, her diarrhea became milder, and she was able to continue S-1 chemotherapy." | 1.48 | The Capsule Endoscopy Findings in S-1-induced Enteritis with Severe Diarrhea during Adjuvant Chemotherapy for Gastric Cancer (with Video). ( Goto, M; Harada, S; Higuchi, K; Kodama, K; Kojima, Y; Nouda, S; Ota, K; Ozaki, H; Takeuchi, T, 2018) |
| "To identify predictive markers for gastric cancer treatment in Chinese patients, we evaluated the association between polymorphisms of the gene encoding cytochrome P450 2A6 (CYP2A6) and outcomes of S-1 plus oxaliplatin (SOX) chemotherapy treatment." | 1.46 | CYP2A6 Polymorphisms Associate with Outcomes of S-1 Plus Oxaliplatin Chemotherapy in Chinese Gastric Cancer Patients. ( Hu, S; Shu, C; Song, Y; Sun, YK; Yang, L; Yang, Y; Yuan, X; Zhang, W; Zhou, A; Zou, S, 2017) |
| "Gemcitabine plus S-1 is a viable treatment alternative to gemcitabine, which is one of the standard treatments in patients with LAPC." | 1.46 | Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data. ( Furuse, J; Hamada, C; Ikari, T; Imai, S; Isayama, H; Ishii, H; Nakai, Y; Okamura, S; Okusaka, T, 2017) |
| "In 62 gastric cancer patients treated with S-1 alone, data relating to the occurrence of gastrointestinal toxicity (diarrhea, vomiting, and nausea) and possible contributing factors were retrospectively collected, and logistic regression analysis was performed." | 1.40 | Reduction in gastrointestinal toxicity by gastric secretion inhibitors during S-1 monotherapy for patients with gastric cancer. ( Chisaki, Y; Hira, D; Morita, SY; Noda, S; Terada, T; Yano, Y, 2014) |
| "The chemotherapy regime was 80 mg/m(2) liposome-paclitaxel given on days 1, 8, 15 and 22, combined with S-1 60 mg (body surface area > 1." | 1.40 | Effect of the weekly administration of liposome-Paclitaxel combined with s-1 on advanced gastric cancer. ( Chen, L; Chen, Q; Chen, Z; Shen, L; Shen, X; Tao, J; Wang, H; Wang, J; Zhang, Y; Zhu, M; Zhuang, Z, 2014) |
| "To observe the local control rate, survival time and side effect of three-dimensional conformal radiation therapy combined with Tegafur for postoperative recurrent rectal carcinoma." | 1.37 | [Effecacy of three-dimensional conformal radiation therapy combined with Tegafur for postoperative recurrent rectal carcinoma]. ( Li, WL; Liu, XH, 2011) |
| "Fifty-one patients with metastatic colorectal cancer were enrolled in the study." | 1.31 | Oral uracil/ftorafur (UFT) plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer. ( Chen, JS; Hsu, KC; Tang, R; Wang, JY; Yang, TS, 2002) |
| " In the CDHP and Oxo treatment groups of rats, the only toxic signs were soft or diarrheal stools on the dosing day." | 1.29 | [Oral single-dose toxicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo]. ( Hayashi, T; Hirota, T; Irimura, K; Ohmae, S; Tanaka, G, 1996) |
| "A 60-year-old female patient with gastric cancer and lymph node and liver metastases was treated with a combination of tegafur and uracil (UFT) (375 mg/m2/day) and mitomycin C (MMC) (5 mg/m2 once weekly)." | 1.29 | A case of advanced gastric cancer complicated by severe toxicity induced by a combination of tegafur, uracil and mitomycin C, and associated with abnormal pharmacokinetics. ( Boku, N; Ishii, H; Kaneko, K; Kusada, O; Muro, K; Muto, M; Ohkuwa, M; Ohtsu, A; Sasaki, Y; Tajiri, H; Yoshida, S, 1996) |
| "Tegafur was administered orally in two or three divided doses." | 1.27 | Phase I evaluation of oral tegafur. ( Bedikian, AY; Bodey, GP; Burgess, MA; Valdivieso, M, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (3.70) | 18.7374 |
| 1990's | 23 (28.40) | 18.2507 |
| 2000's | 24 (29.63) | 29.6817 |
| 2010's | 30 (37.04) | 24.3611 |
| 2020's | 1 (1.23) | 2.80 |
| Authors | Studies |
|---|---|
| Kawakami, K | 1 |
| Aoyama, T | 1 |
| Yokokawa, T | 1 |
| Kobayashi, K | 1 |
| Takahari, D | 1 |
| Chin, K | 1 |
| Ide, T | 1 |
| Machida, Y | 1 |
| Yamaguchi, K | 2 |
| Hama, T | 1 |
| Hamada, C | 1 |
| Okusaka, T | 2 |
| Ikari, T | 1 |
| Isayama, H | 2 |
| Furuse, J | 3 |
| Ishii, H | 2 |
| Nakai, Y | 2 |
| Imai, S | 1 |
| Okamura, S | 1 |
| Kudo, M | 2 |
| Moriguchi, M | 1 |
| Numata, K | 1 |
| Hidaka, H | 1 |
| Tanaka, H | 1 |
| Ikeda, M | 1 |
| Kawazoe, S | 1 |
| Ohkawa, S | 1 |
| Sato, Y | 2 |
| Kaneko, S | 1 |
| Takeuchi, M | 3 |
| Fang, X | 1 |
| Date, Y | 1 |
| Li, J | 2 |
| Xu, R | 1 |
| Xu, J | 1 |
| Denda, T | 1 |
| Ikejiri, K | 1 |
| Shen, L | 2 |
| Toh, Y | 1 |
| Shimada, K | 1 |
| Kato, T | 2 |
| Sakai, K | 1 |
| Yamamoto, M | 1 |
| Mishima, H | 2 |
| Wang, J | 2 |
| Baba, H | 2 |
| Yang, L | 1 |
| Zou, S | 1 |
| Shu, C | 1 |
| Song, Y | 1 |
| Sun, YK | 1 |
| Zhang, W | 1 |
| Zhou, A | 1 |
| Yuan, X | 1 |
| Yang, Y | 1 |
| Hu, S | 1 |
| Ota, K | 1 |
| Takeuchi, T | 1 |
| Kodama, K | 1 |
| Ozaki, H | 1 |
| Harada, S | 1 |
| Kojima, Y | 1 |
| Nouda, S | 1 |
| Goto, M | 2 |
| Higuchi, K | 1 |
| Winther, SB | 2 |
| Bjerregaard, JK | 1 |
| Schonnemann, KR | 1 |
| Ejlsmark, MW | 1 |
| Krogh, M | 2 |
| Jensen, HA | 2 |
| Pfeiffer, P | 4 |
| Matsuda, C | 1 |
| Honda, M | 1 |
| Tanaka, C | 1 |
| Kondo, K | 1 |
| Takahashi, T | 1 |
| Kosugi, C | 1 |
| Tokunaga, Y | 1 |
| Takemoto, H | 1 |
| Kim, HM | 1 |
| Sakamoto, J | 1 |
| Oba, K | 1 |
| Toyomasu, Y | 1 |
| Mochiki, E | 1 |
| Yanai, M | 1 |
| Suzuki, M | 2 |
| Yanoma, T | 1 |
| Kimura, A | 1 |
| Kogure, N | 1 |
| Ogata, K | 1 |
| Kuwano, H | 1 |
| Chen, L | 1 |
| Chen, Q | 1 |
| Zhuang, Z | 1 |
| Zhang, Y | 2 |
| Tao, J | 1 |
| Shen, X | 1 |
| Chen, Z | 1 |
| Zhu, M | 1 |
| Wang, H | 1 |
| Ohue, M | 1 |
| Hamaguchi, T | 2 |
| Ito, Y | 1 |
| Sakai, D | 1 |
| Noura, S | 1 |
| Kinugasa, Y | 1 |
| Fujita, S | 1 |
| Shimada, Y | 2 |
| Saito, N | 1 |
| Moriya, Y | 1 |
| Nakamura, T | 2 |
| Yamashita, K | 2 |
| Sato, T | 3 |
| Ema, A | 1 |
| Naito, M | 2 |
| Watanabe, M | 4 |
| Chisaki, Y | 1 |
| Noda, S | 1 |
| Hira, D | 1 |
| Morita, SY | 1 |
| Yano, Y | 2 |
| Terada, T | 1 |
| Saito, K | 1 |
| Sasaki, T | 1 |
| Takahara, N | 1 |
| Hamada, T | 1 |
| Mizuno, S | 1 |
| Miyabayashi, K | 1 |
| Yamamoto, K | 1 |
| Mohri, D | 1 |
| Kogure, H | 1 |
| Yamamoto, N | 1 |
| Hirano, K | 1 |
| Ijichi, H | 1 |
| Tateishi, K | 1 |
| Tada, M | 1 |
| Koike, K | 1 |
| Namikawa, T | 1 |
| Munekage, E | 1 |
| Maeda, H | 1 |
| Kitagawa, H | 1 |
| Kobayashi, M | 1 |
| Hanazaki, K | 1 |
| Abdel-Rahman, O | 1 |
| ElHalawani, H | 1 |
| Essam-Eldin, S | 1 |
| Zubcevic, K | 1 |
| Qvortrup, C | 1 |
| Vestermark, LW | 1 |
| Sorbye, H | 1 |
| Satoi, S | 1 |
| Yanagimoto, H | 1 |
| Yamamoto, T | 1 |
| Ohe, C | 1 |
| Miyasaka, C | 1 |
| Uemura, Y | 1 |
| Hirooka, S | 1 |
| Yamaki, S | 1 |
| Ryota, H | 1 |
| Michiura, T | 1 |
| Inoue, K | 1 |
| Matsui, Y | 1 |
| Tanigawa, N | 1 |
| Kon, M | 1 |
| Hayakawa, K | 2 |
| Tomita, N | 1 |
| Noda, M | 1 |
| Kamikonya, N | 1 |
| Watanabe, T | 1 |
| Kato, D | 1 |
| Sakai, Y | 1 |
| Hiraoka, M | 1 |
| Shimada, M | 1 |
| Ikushima, H | 1 |
| Oya, N | 1 |
| Oya, M | 1 |
| Nemoto-Murofushi, K | 1 |
| Arima, S | 1 |
| Shimizu, K | 1 |
| Okamoto, T | 1 |
| Toki, M | 1 |
| Suzuki, Y | 1 |
| Okano, N | 1 |
| Naruge, D | 1 |
| Kawai, K | 1 |
| Kobayashi, T | 1 |
| Kasuga, A | 1 |
| Kitamura, H | 1 |
| Takasu, A | 1 |
| Nagashima, F | 1 |
| Sugiyama, M | 1 |
| Bin, Q | 1 |
| Liao, C | 1 |
| Cao, Y | 1 |
| Gao, F | 1 |
| Hsu, CH | 1 |
| Shen, YC | 1 |
| Lin, ZZ | 1 |
| Chen, PJ | 1 |
| Shao, YY | 1 |
| Ding, YH | 1 |
| Hsu, C | 1 |
| Cheng, AL | 1 |
| Hong, YS | 1 |
| Lee, JL | 2 |
| Park, JH | 1 |
| Kim, JH | 1 |
| Yoon, SN | 1 |
| Lim, SB | 1 |
| Yu, CS | 1 |
| Kim, MJ | 1 |
| Jang, SJ | 1 |
| Lee, JS | 2 |
| Kim, JC | 1 |
| Kim, TW | 2 |
| Tsunoda, A | 1 |
| Nakao, K | 1 |
| Ozawa, H | 2 |
| Hatate, K | 1 |
| Onosato, W | 1 |
| Ihara, A | 1 |
| Koizumi, W | 1 |
| Okayasu, I | 1 |
| Chon, HJ | 1 |
| Rha, SY | 1 |
| Park, HS | 1 |
| Shin, SJ | 1 |
| Kim, HS | 1 |
| Roh, JK | 1 |
| Noh, SH | 1 |
| Chung, HC | 1 |
| Jeung, HC | 1 |
| Liu, XH | 1 |
| Li, WL | 1 |
| Zhu, QC | 1 |
| Jin, ZM | 1 |
| Komatsu, Y | 2 |
| Yuki, S | 2 |
| Sogabe, S | 1 |
| Fukushima, H | 1 |
| Nakatsumi, H | 1 |
| Kobayashi, Y | 1 |
| Iwanaga, I | 1 |
| Nakamura, M | 1 |
| Hatanaka, K | 1 |
| Miyagishima, T | 2 |
| Munakata, M | 1 |
| Meguro, T | 1 |
| Tateyama, M | 1 |
| Sakata, Y | 1 |
| Ozgen, Z | 1 |
| Ozden, S | 1 |
| Dane, F | 1 |
| Atasoy, BM | 1 |
| Akgun, Z | 1 |
| Yumuk, PF | 1 |
| Huang, DZ | 1 |
| Xiong, JP | 1 |
| Xu, N | 1 |
| Yan, Z | 1 |
| Zhuang, ZX | 1 |
| Yu, Z | 1 |
| Wan, HP | 1 |
| Deng, T | 1 |
| Zheng, RS | 1 |
| Guo, ZQ | 1 |
| Hu, CH | 1 |
| Wang, ML | 1 |
| Yu, ZH | 1 |
| Yao, Y | 1 |
| Meng, JC | 1 |
| Ba, Y | 1 |
| Yang, TS | 1 |
| Wang, JY | 1 |
| Tang, R | 1 |
| Hsu, KC | 1 |
| Chen, JS | 1 |
| Petrioli, R | 1 |
| Sabatino, M | 1 |
| Fiaschi, AI | 1 |
| Marsili, S | 1 |
| Pozzessere, D | 1 |
| Messinese, S | 1 |
| Correale, P | 1 |
| Civitelli, S | 1 |
| Tanzini, G | 1 |
| Tani, F | 1 |
| De Martino, A | 1 |
| Marzocca, G | 1 |
| Lorenzi, M | 1 |
| Giorgi, G | 1 |
| Francini, G | 1 |
| Saeki, T | 1 |
| Takashima, S | 1 |
| Sano, M | 1 |
| Horikoshi, N | 1 |
| Miura, S | 1 |
| Shimizu, S | 1 |
| Morimoto, K | 1 |
| Kimura, M | 1 |
| Taguchi, T | 4 |
| Sakuyama, T | 1 |
| Yokoyama, M | 1 |
| Ogawa, M | 1 |
| Takao, Y | 1 |
| Sato, K | 1 |
| Kawahara, H | 1 |
| Anazawa, S | 1 |
| Yamazaki, Y | 1 |
| Hirai, K | 1 |
| Feliu, J | 5 |
| Vicent, JM | 1 |
| García-Girón, C | 2 |
| Constela, M | 1 |
| Fonseca, E | 1 |
| Aparicio, J | 1 |
| Lomas, M | 2 |
| Antón-Aparicio, L | 1 |
| Dorta, FJ | 1 |
| Gonzalez-Baron, M | 2 |
| Suzuki, S | 1 |
| Harada, N | 1 |
| Takeo, Y | 1 |
| Tanaka, S | 1 |
| Hayashi, T | 2 |
| Hanyu, F | 1 |
| Nio, Y | 1 |
| Hashimoto, K | 1 |
| Yano, S | 1 |
| Itakura, M | 1 |
| Koike, M | 1 |
| Endo, S | 1 |
| Tsuji, M | 1 |
| Higami, T | 1 |
| Maruyama, R | 1 |
| Bennouna, J | 2 |
| Perrier, H | 1 |
| Paillot, B | 1 |
| Priou, F | 1 |
| Jacob, JH | 1 |
| Hebbar, M | 1 |
| Bordenave, S | 1 |
| Seitz, JF | 1 |
| Cvitkovic, F | 1 |
| Dorval, E | 1 |
| Malek, K | 1 |
| Tonelli, D | 1 |
| Douillard, JY | 2 |
| Goto, A | 1 |
| Yamada, Y | 1 |
| Yasui, H | 1 |
| Kato, K | 1 |
| Muro, K | 3 |
| Shirao, K | 1 |
| Inaba, Y | 1 |
| Yamaura, H | 1 |
| Shimamoto, H | 1 |
| Nishiofuku, H | 1 |
| Oyama, T | 1 |
| Kanemitsu, Y | 1 |
| Sawaki, A | 1 |
| Arai, Y | 1 |
| Mizushima, T | 1 |
| Mizuno, H | 1 |
| Ito, T | 1 |
| Hoki, M | 1 |
| Souma, Y | 1 |
| Iwamoto, T | 1 |
| Kanou, T | 1 |
| Nakamori, Y | 1 |
| Iwase, K | 1 |
| Hyodo, I | 1 |
| Asaka, M | 1 |
| Kang, HJ | 1 |
| Kang, YK | 1 |
| Ryu, MH | 1 |
| Chang, HM | 1 |
| Sohn, HJ | 1 |
| Kim, H | 1 |
| Etienne-Grimaldi, MC | 1 |
| François, E | 1 |
| Cardot, JM | 1 |
| Renée, N | 1 |
| Gamelin, E | 1 |
| Château, Y | 1 |
| Milano, G | 1 |
| Shien, T | 1 |
| Shimizu, C | 1 |
| Akashi-Tanaka, S | 1 |
| Yonemori, K | 1 |
| Kohno, T | 1 |
| Hojo, T | 1 |
| Ando, M | 1 |
| Katsumata, N | 1 |
| Kinoshita, T | 1 |
| Fujiwara, Y | 1 |
| Uedo, N | 1 |
| Narahara, H | 1 |
| Ishihara, R | 1 |
| Takiuchi, H | 1 |
| Fujitani, K | 1 |
| Hirao, M | 1 |
| Tsujinaka, T | 1 |
| Imano, M | 1 |
| Furukawa, H | 1 |
| Tsukuma, H | 1 |
| Bedikian, AY | 1 |
| Bodey, GP | 1 |
| Valdivieso, M | 1 |
| Burgess, MA | 1 |
| Inokuchi, K | 1 |
| Hattori, T | 1 |
| Abe, O | 2 |
| Ogawa, N | 2 |
| Saltz, LB | 1 |
| Leichman, CG | 2 |
| Young, CW | 1 |
| Muggia, FM | 2 |
| Conti, JA | 1 |
| Spiess, T | 1 |
| Jeffers, S | 2 |
| Leichman, LP | 1 |
| Solé, LA | 1 |
| Albanell, J | 1 |
| Bellmunt, J | 1 |
| Ribas, A | 1 |
| Gallego, OS | 1 |
| Carulla, J | 1 |
| Pazdur, R | 1 |
| Lassere, Y | 1 |
| Rhodes, V | 1 |
| Ajani, JA | 1 |
| Sugarman, SM | 1 |
| Patt, YZ | 1 |
| Jones, DV | 1 |
| Markowitz, AB | 1 |
| Abbruzzese, JL | 1 |
| Bready, B | 1 |
| Daniels, M | 1 |
| Díaz-Rubio, E | 4 |
| Guillem, V | 1 |
| Montero, JM | 1 |
| García-Conde, J | 1 |
| Estapé, J | 1 |
| Martín, M | 2 |
| Herranz, C | 1 |
| Ordoñez, A | 4 |
| Galán, A | 1 |
| Manzuik, LV | 1 |
| Perevodchikova, NI | 1 |
| Gorbunova, VA | 1 |
| Singin, AS | 1 |
| Gerasimova, GS | 1 |
| Bychkov, MB | 1 |
| Rustum, YM | 1 |
| Creaven, PJ | 1 |
| Espinosa, E | 4 |
| de Castro, J | 3 |
| Zamora, P | 3 |
| Gomez-Navarro, J | 2 |
| Espinosa, J | 2 |
| Vilches, Y | 1 |
| de la Gandara, I | 2 |
| Kim, YH | 2 |
| Cheong, SK | 1 |
| Lee, JD | 1 |
| Park, JS | 1 |
| Shin, SW | 2 |
| Kim, JS | 2 |
| González Barón, M | 3 |
| García-Alfonso, P | 1 |
| Belón, J | 2 |
| Blanco, E | 1 |
| Garrido, P | 2 |
| Boku, N | 1 |
| Ohtsu, A | 1 |
| Kaneko, K | 1 |
| Muto, M | 1 |
| Ohkuwa, M | 1 |
| Sasaki, Y | 1 |
| Tajiri, H | 1 |
| Yoshida, S | 1 |
| Kusada, O | 1 |
| Tanaka, G | 1 |
| Irimura, K | 1 |
| Hirota, T | 1 |
| Ohmae, S | 1 |
| García Girón, C | 2 |
| Colmenarejo, A | 1 |
| Jalón, JI | 1 |
| Fernández, Y | 1 |
| Kurokawa, H | 1 |
| Miura, K | 1 |
| Yamashita, Y | 1 |
| Tokudome, S | 1 |
| Murata, T | 1 |
| Kajiyama, M | 1 |
| Abad, A | 1 |
| Navarro, M | 1 |
| Sastre, J | 1 |
| Marcuello, E | 1 |
| Aranda, E | 1 |
| Gallén, M | 1 |
| Fernandez-Martos, C | 1 |
| Martín, C | 1 |
| Casado, A | 1 |
| López-Martin, JA | 1 |
| Rodriguez-Lescure, A | 1 |
| Nieto, Y | 1 |
| Ayala, F | 1 |
| González-Larriba, JL | 1 |
| Garcia Carbonero, I | 1 |
| Sastre Valera, J | 1 |
| Perez Segura, P | 1 |
| García Alfonso, P | 1 |
| Kurihara, M | 1 |
| Kim, BS | 1 |
| Park, YT | 1 |
| Kim, JG | 1 |
| Shirasaka, T | 1 |
| Shimamoto, Y | 1 |
| Fukushima, M | 1 |
| Yamashita, F | 1 |
| Tanaka, M | 1 |
| Fukumori, K | 1 |
| Ando, E | 1 |
| Kato, O | 1 |
| Yamamoto, H | 1 |
| Fukuda, H | 1 |
| Kusaba, T | 1 |
| Tanikawa, K | 1 |
| Sata, M | 1 |
| Wu, X | 1 |
| Spicer, D | 1 |
| Groshen, S | 1 |
| Leichman, L | 1 |
| Chan, KK | 1 |
| de la Torre, A | 1 |
| Ramos, S | 1 |
| Valcárcel, FJ | 1 |
| Candal, A | 1 |
| Regueiro, CA | 1 |
| Romero, J | 1 |
| Magallón, R | 1 |
| Salinas, J | 1 |
| de las Heras, M | 1 |
| Veiras, C | 1 |
| Tisaire, JL | 1 |
| Aragón, G | 1 |
| Childs, HA | 1 |
| Spencer, SA | 1 |
| Raben, D | 1 |
| Bonner, JA | 1 |
| Newsome, J | 1 |
| Robert, F | 1 |
| Yoshisue, K | 1 |
| Hironaga, K | 1 |
| Yamaguchi, S | 1 |
| Yamamoto, A | 1 |
| Nagayama, S | 1 |
| Kawaguchi, Y | 1 |
| Bokemeyer, C | 1 |
| Hartmann, JT | 1 |
| Mayer, F | 1 |
| Böhlke, I | 1 |
| Kanz, L | 1 |
| Von Pawel, J | 1 |
| Derigs, G | 1 |
| Schröder, M | 1 |
| Alonso, V | 1 |
| Escudero, P | 1 |
| Zorrilla, M | 1 |
| Isla, MD | 1 |
| Herrero, A | 1 |
| Mayordomo, JI | 1 |
| Martinez-Trufero, J | 1 |
| Sáenz, A | 1 |
| Tres, A | 1 |
| Antón, A | 1 |
| Chakrapee-Sirisuk, S | 1 |
| Sinlarat, P | 1 |
| Lohsiriwat, D | 1 |
| Lert-Akayamanee, N | 1 |
| Nimmanwudipong, T | 1 |
| Srimuninnimit, V | 1 |
| Vathanophas, V | 1 |
| Arch-Yaemsuan, P | 1 |
| Boonnuch, W | 1 |
| Adimi, P | 1 |
| Hansen, F | 1 |
| Kjaer, M | 1 |
| Aabo, K | 1 |
| Keldsen, N | 1 |
| Sandberg, E | 1 |
| Jakobsen, A | 1 |
| Ohyama, M | 1 |
| Matsumura, M | 1 |
| Katsuta, K | 1 |
| Nobori, T | 1 |
| Matsuyama, H | 1 |
| Fukami, K | 1 |
| Kiyota, R | 1 |
| Yano, H | 1 |
| Shima, T | 1 |
| Ogawa, K | 1 |
| Terasawa, T | 1 |
| Yoshida, Y | 1 |
| Tominaga, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Paclitaxel Liposome Plus S-1 as Neoadjuvant Chemotherapy for Advanced Gastric Cancer[NCT02163291] | Phase 2 | 30 participants (Anticipated) | Interventional | 2013-12-31 | Not yet recruiting | ||
| Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity in Patients With Solid Tumors: A Retrospective, International and Non-interventional Study[NCT04260269] | 200 participants (Anticipated) | Observational | 2018-06-01 | Enrolling by invitation | |||
| Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer[NCT00569790] | Phase 2 | 53 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449] | Phase 3 | 338 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for tegafur and Diarrhea
| Article | Year |
|---|---|
S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Combinations; Fluorouracil; Humans; I | 2016 |
Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans | 2011 |
[Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Topics: Animals; Anorexia; Antimetabolites, Antineoplastic; Diarrhea; Dogs; Drug Combinations; Female; Fluor | 1998 |
54 trials available for tegafur and Diarrhea
| Article | Year |
|---|---|
S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Diarrhea; Double-Blind Method; Dru | 2017 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; China; Col | 2017 |
A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Diarrhea; D | 2018 |
A prospective pilot study of an elemental nutritional supplement for prevention of oral mucositis during S-1 adjuvant chemotherapy for gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Case-Control Studie | 2019 |
A phase I trial of preoperative S-1 in combination with oxaliplatin and pelvic radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis.
Topics: Adenocarcinoma; Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; A | 2015 |
Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: impact on long-term clinical outcomes and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Analysis of Variance; Antineoplastic Combined Chemo | 2014 |
A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Dose-Respon | 2014 |
Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer.
Topics: Acetamides; Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic | 2014 |
Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2016 |
A multicenter phase I study of preoperative chemoradiotherapy with S-1 and irinotecan for locally advanced lower rectal cancer (SAMRAI-1).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Diarrh | 2016 |
A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Co | 2017 |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Benzenesul | 2010 |
Phase I study of preoperative chemoradiation with s-1 and oxaliplatin in patients with locally advanced resectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2011 |
A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Disease-Free Su | 2011 |
[Efficacy and side effects of combination therapy of oxaliplatin and S-1 for colorectal cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Colo | 2011 |
Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2012 |
Health-related quality of life during postoperative chemoradiotherapy with oral uracil-tegafur and leucovorin in rectal cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2013 |
[A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; | 2012 |
UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; C | 2004 |
[A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer].
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Breast Neoplasms; Diarrhea; Drug Administrat | 2004 |
Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Ad | 2004 |
Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therap | 2005 |
High-dose radiotherapy and concurrent UFT plus l-leucovorin in locally advanced rectal cancer: a phase I trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2005 |
'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2006 |
Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agent | 2006 |
[S-1 combined with weekly dosing of cisplatin for metastatic gastric cancer].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplat | 2006 |
[Irinotecan plus oral S-1 in patients with advanced gastric cancer-biweekly IRIS regimen].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cap | 2006 |
Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; | 2008 |
A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; | 2007 |
Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002).
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplas | 2007 |
Postoperative adjuvant chemotherapy for gastric carcinoma. Analysis of data on 1805 patients followed for 5 years.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Moda | 1984 |
A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Color | 1995 |
Phase II trial of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1995 |
Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 1994 |
Phase II trial of UFT activity in pretreated breast cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; A | 1993 |
Initial clinical experience with oral ftorafur and oral 6R,S leucovorin in advanced colorectal carcinoma.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea | 1993 |
Cisplatin and UFT modulated with leucovorin for the treatment of Advanced non-small-cell lung cancer.
Topics: Abdominal Pain; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1996 |
Phase II trial of Oral UFT and leucovorin in advanced gastric carcinoma.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antidotes; Antimetabolites, Antineop | 1996 |
Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Anemia; Antidotes; Antimetabolites, Antineoplast | 1996 |
[Evaluation of neo-adjuvant chemotherapy for oral squamous cell carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1997 |
A preliminary report of a phase II trial. UFT plus oral folinic acid as therapy for metastatic colorectal cancer in older patients. Spanish Group for the Treatment of Gastrointestinal Tumors (TTd Group).
Topics: Aged; Aged, 80 and over; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl | 1997 |
Neoadjuvant therapy with cisplatin/fluorouracil vs cisplatin/UFT in locally advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 1997 |
The UFT/leucovorin/etoposide regimen for the treatment of advanced gastric cancer. Oncopaz Cooperative Group.
Topics: Anemia; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Combinations; Etop | 1997 |
UFT plus cisplatin for advanced gastric cancer.
Topics: Adolescent; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrh | 1997 |
A phase II trial. Oral UFT and leucovorin in patients with advanced gastric carcinoma.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Diarrhea; Drug Co | 1997 |
A crossover study of oral administration of UFT in chronic liver disease: comparison of continuous and intermittent schedules.
Topics: Administration, Oral; Aged; Area Under Curve; Carcinoma, Hepatocellular; Chronic Disease; Cross-Over | 1998 |
Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Cohor | 1996 |
Phase II study of radiochemotherapy with UFT and low-dose oral leucovorin in patients with unresectable rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Diarrhea; Disease-Free S | 1999 |
A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dia | 2000 |
UFT/leucovorin plus weekly paclitaxel in the treatment of solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Dose-Re | 2000 |
Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Coh | 2001 |
Uracil with ftorafur and low dose oral folinic acid in advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; | 2001 |
Oral fluoropyrimidines in the treatment of advanced colorectal cancer--results of two consecutive phase II trials.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2002 |
24 other studies available for tegafur and Diarrhea
| Article | Year |
|---|---|
The Combined Use of 5 or More Drugs Is a Factor Related to Lower Adherence to S-1 in S-1 and Oxaliplatin Treatment for Advanced Gastric Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2021 |
Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.
Topics: Aftercare; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; | 2017 |
CYP2A6 Polymorphisms Associate with Outcomes of S-1 Plus Oxaliplatin Chemotherapy in Chinese Gastric Cancer Patients.
Topics: Adult; Aged; Asian People; China; Cytochrome P-450 CYP2A6; Diarrhea; Drug Combinations; Drug Therapy | 2017 |
The Capsule Endoscopy Findings in S-1-induced Enteritis with Severe Diarrhea during Adjuvant Chemotherapy for Gastric Cancer (with Video).
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capsule Endo | 2018 |
S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Coho | 2018 |
Effect of the weekly administration of liposome-Paclitaxel combined with s-1 on advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease-Free Survival; Drug A | 2014 |
Reduction in gastrointestinal toxicity by gastric secretion inhibitors during S-1 monotherapy for patients with gastric cancer.
Topics: Aged; Diarrhea; Dose-Response Relationship, Drug; Drug Combinations; Female; Gastric Mucosa; Histami | 2014 |
Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy.
Topics: Adult; Aged; Ascites; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuv | 2017 |
[Compliance of oral UFT plus leucovorin adjuvant chemotherapy in patients who underwent curative resection for colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy | 2010 |
[Effecacy of three-dimensional conformal radiation therapy combined with Tegafur for postoperative recurrent rectal carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Diarrhea; E | 2011 |
Oral uracil/ftorafur (UFT) plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Diarrhea; Dose-Response Relationship, Drug; D | 2002 |
[Home chemotherapy by concomitant UFT + Leucovorin (po.) in postoperative colorectal cancer patients assessed with Dukes D and curability C colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Administration | 2004 |
[A case of recurrent gallbladder cancer responding to combination chemotherapy of TS-1 and CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Diarrhea | 2004 |
[Retrospective analysis of tegafur/uracil (UFT) plus oral leucovorin (LV) regimen in patients with advanced colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2006 |
[Efficacy of uracil/tegafur (UFT) plus oral Leucovorin (LV) therapy for colorectal cancer in elderly patients].
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2006 |
Clinical efficacy of S-1 in pretreated metastatic breast cancer patients.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms | 2008 |
Phase I evaluation of oral tegafur.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Blood Cell Count; Diarrhea; Dose-Response Relatio | 1983 |
A case of advanced gastric cancer complicated by severe toxicity induced by a combination of tegafur, uracil and mitomycin C, and associated with abnormal pharmacokinetics.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Marrow Diseas | 1996 |
[Oral single-dose toxicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo].
Topics: Administration, Oral; Alopecia; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 1996 |
Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Antidotes; Antimetabolites, Antineop | 1997 |
Preliminary results. UFT/methotrexate/leucovorin for breast Ca patients in progression after HDCT/PBPC support.
Topics: Adult; Anemia; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea | 1997 |
Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Colon; Diarrhea; Digestive System; Drug Combi | 2000 |
[A comparative study of UFT enteric-coated granules with UFT capsules on the occurrence of side effects in patients with head and neck cancers--a special attention to the upper gastrointestinal tract disorders].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capsules; Diarrhea; | 1990 |
[A comparative study of 5'-DFUR and tegafur in recurrent breast cancer].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Breast Neoplasms; Capsules; Diar | 1985 |